Can-Fite reports piclidenoson lowered kidney protein-loss marker in preclinical Lowe syndrome work
Published preclinical data show the oral A3 adenosine receptor agonist reduced a urinary proteinuria marker by 48–80%, and an Italian Phase II study in five adults is under regulatory review.
Can-Fite BioPharma announced on 12 November 2026 that preclinical research on its oral A3 adenosine receptor agonist piclidenoson in Lowe syndrome has been published in the journal Signal Transduction and Targeted Therapy.
The work used patient-derived cells, kidney organoids and a humanised mouse model. According to the company, five months of treatment lowered a urinary marker of low-molecular-weight proteinuria by 48% to 80%.
Can-Fite also said a planned open-label Phase II study in five adults with Lowe syndrome is currently under review by Italian health authorities. The company's announcement, as summarised, gives no start date or approval timeline, and the full source text was not available for further detail.
The findings are preclinical, so they do not show whether the effect will translate into patients. The Phase II study, if authorised, would be the first step in testing that question in people.
Why it matters
- The data are preclinical only; no clinical efficacy or safety conclusions in Lowe syndrome can be drawn yet.
- Watch for a decision from the Italian authorities on the planned five-patient open-label Phase II study.
- A very small adult study would give limited evidence, so any regulatory or market-access planning would depend on later and larger data.
Company's press release (SEC filing): Can-Fite BioPharma Ltd. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
IRulya Therapeutics reports $105.2M cash as LAM-001 Phase 2 readouts approach
Cerenome reports first CNSide revenue and completes enrolment in Phase 2 glioblastoma trial
BeyondSpring wins FDA Fast Track for plinabulin plus docetaxel in post-immunotherapy NSCLC
Valneva: 94% of adults still seroresponders five years after single IXCHIQ dose
GH Research posts $46.6M nine-month loss as GH001 depression programme nears pivotal stage
